Cover Image
市場調查報告書

全球的重組凝血因子市場預測

Global Recombinant Coagulation Factors Market Outlook: 2015-2020

出版商 Meticulous Market Research Pvt.Ltd. 商品編碼 348586
出版日期 內容資訊 英文
商品交期: 最快1-2個工作天內
價格
Back to Top
全球的重組凝血因子市場預測 Global Recombinant Coagulation Factors Market Outlook: 2015-2020
出版日期: 2015年11月24日 內容資訊: 英文
簡介

全球重組凝血因子市場過去數年大幅成長。這是由於血友病患者的增加,診斷率的上升,凝血因子相關研究開發數量的增加等。該市場預計從2015年到2020年以年複合成長率7.6%擴大,預計2020年以到達99億3,970萬美元附近。

,被

本報告提供全球重組凝血因子市場相關調查、市場現狀與規模、市場佔有率、至2020年的預測、各類型/各血友病/各終端用戶/各地區趨勢、競爭預測,及進入的主要企業簡介彙整。

第1章 重組凝血因子市場簡介

第2章 摘要整理

第3章 市場概要

  • 促進要素
  • 阻礙要素
  • 機會
  • 市場佔有率分析
  • 開發平台分析

第4章 各類型市場

  • 重組因素VIII
  • 重組因素IX
  • Von Willebrand' s因子

第5章 按血友病市場

  • A型血友病
  • B型血友病

第6章 各終端用戶市場

  • 醫院
  • 研究機關
  • 學術機構

第7章 各地區

  • 北美
  • 歐洲
  • 亞太地區
  • 其他

第8章 競爭環境

  • 協定、聯合、聯盟、合資企業
  • 擴充
  • 合併、收購
  • 新產品上市
  • 其他

第9章 企業簡介

  • Baxter International Inc
  • Grifols International SA
  • CSL Ltd.
  • Octapharma AG
  • Kedrion S.P.A.
  • Novo Nordisk A/S
  • Pfizer Inc.
  • Bayer AG
  • Biogen Idec

圖表

目錄
Product Code: BT 1141

The global recombinant coagulation factors market has witnessed major growth over the past few years. The growth of this market is mainly due to increasing number of hemophilia patients, growing diagnosis rates, and rising number of research and development on coagulation factors. In addition, increasing prophylactic treatment for hemophilia across the globe is further expected to drive the growth of this market. However, high cost of hemophilia treatment and low cost plasma coagulation factor alternatives to recombinant coagulation factors are hampering the growth of this market. Many players are focusing on Asia Pacific region to expand their businesses as this market is most lucrative for the recombinant coagulation factors.

The global recombinant coagulation factors market is expected to reach around $9,939.7 million in 2020 and grow at a CAGR of 7.6% during the forecast period of 2015 to 2020. The global market is segmented on the basis of products, by hemophilia type, and geography. On the basis of product, recombinant coagulation factors market is segmented into three classes, namely, recombinant factor VIII, recombinant factor IX, and VonWillebrandfactor. By hemophilia type, global recombinant coagulation factors market is divided into hemophilia A and hemophilia B. By end user, global recombinant coagulation factors market is segmented into hospitals and clinics, research organizations, and academic institutes.

In 2014, the recombinant factor VIII accounted for the largest share of the global recombinant coagulation factor market. The large share of this segment can be attributed to increasing number of hemophilia A patients and rising prophylaxis treatment.

In 2014, North America dominated the market, with the largest share of 37.8%. The increasing number of hemophilia patients in the U.S., increasing diagnosis rates, and growing prophylactic treatment for prevention of bleeding helped the growth of this market. In addition, rising research on recombinant factor VIII is further expected to drive the growth of this market.

Major companies in the global recombinant coagulation factor market are Baxter International Inc (U.S.), Grifols International SA (Spain), CSL Ltd. (Australia), Octapharma AG (Switzerland), Novo Nordisk A/S (Denmark), Biogen Idec (U.S.), Bayer AG (Germany),Kedrion S.P.A. (Italy), and Pfizer Inc. (U.S.).

Source: Expert Interviews, Government Authorities, Related associations/Institutes, Related Research Publications, Government Publications, Company Press Releases, Company Annual Reports, Company Websites, Company Publications, SEC Filings, Meticulous Research Analysis.

Table of Contents

1. Introduction to Global Recombinant Coagulation Factors Market

  • 1.1. Global Recombinant Coagulation Factors Market Ecosystem
    • 1.1.1. Recombinant Coagulation Factors Market Types
    • 1.1.2. Recombinant Coagulation Factors Market hemophilia type
    • 1.1.3. Recombinant Coagulation Factors Market End-users
  • 1.2. Report Elucidation
  • 1.3. Market Buzz and Foreground
  • 1.4. Research Methodology

2. Executive Summary

3. Market Insights

  • 3.1. Drivers
  • 3.2. Restraints
  • 3.3. Opportunities
  • 3.4. Market Share Analysis
  • 3.5. Recombinant Coagulation Factors Pipeline Analysis

4. Global Recombinant Coagulation Factors- Market Crackdown ($ Value Analysis), By Type

  • 4.1. Recombinant Factor VIII
  • 4.2. Recombinant Factor IX
  • 4.3. VonWillebrandFractor

5. Global Recombinant Coagulation Factors- Market Crackdown ($ Value Analysis), by hemophilia type

  • 5.1. Hemophilia A
  • 5.2. Hemophilia B

6. Global Recombinant Coagulation Factors- Market Crackdown ($ Value Analysis), by End user

  • 6.1. Hospitals
  • 6.2. Research Organization
  • 6.3. Academic Institutes

7. Recombinant Coagulation Factors – Market Crackdown ($ Value Analysis, by Geography

  • 7.1.1. North America
    • 7.1.1.1. U.S.
    • 7.1.1.2. Canada
  • 7.1.2. Europe
    • 7.1.2.1. U.K.
    • 7.1.2.2. France
    • 7.1.2.3. Germany
    • 7.1.2.4. Italy
    • 7.1.2.5. Spain
    • 7.1.2.6. Rest of Europe
  • 7.1.3. Asia-Pacific
    • 7.1.3.1. China
    • 7.1.3.2. Japan
    • 7.1.3.3. India
    • 7.1.3.4. Rest of Asia-Pacific
  • 7.1.4. RoW
    • 7.1.4.1. Latin America
    • 7.1.4.2. Africa
    • 7.1.4.3. Middle East

8. Global Recombinant Coagulation Factors Market- Competitive Landscape

  • 8.1. Agreements, Collaborations, Partnerships, and Joint Ventures
  • 8.2. Expansions
  • 8.3. Mergers & Acquisitions
  • 8.4. New Product Launches
  • 8.5. Other Developments

9. Company Profiles

  • 9.1. Baxter International Inc
    • 9.1.1. Company Overview
    • 9.1.2. Financials
    • 9.1.3. Products & Services
    • 9.1.4. Recent Developments
  • 9.2. Grifols International SA
    • 9.2.1. Company Overview
    • 9.2.2. Financials
    • 9.2.3. Products & Services
    • 9.2.4. Recent Developments
  • 9.3. CSL Ltd.
    • 9.3.1. Company Overview
    • 9.3.2. Financials
    • 9.3.3. Products & Services
    • 9.3.4. Recent Developments
  • 9.4. Octapharma AG
    • 9.4.1. Company Overview
    • 9.4.2. Financials
    • 9.4.3. Products & Services
    • 9.4.4. Recent Developments
  • 9.5. Kedrion S.P.A.
    • 9.5.1. Company Overview
    • 9.5.2. Financials
    • 9.5.3. Products & Services
    • 9.5.4. Recent Developments
  • 9.6. Novo Nordisk A/S
    • 9.6.1. Company Overview
    • 9.6.2. Financials
    • 9.6.3. Products & Services
    • 9.6.4. Recent Developments
  • 9.7. Pfizer Inc.
    • 9.7.1. Company Overview
    • 9.7.2. Financials
    • 9.7.3. Products & Services
    • 9.7.4. Recent Developments
  • 9.8. Bayer AG
    • 9.8.1. Company Overview
    • 9.8.2. Financials
    • 9.8.3. Products & Services
    • 9.8.4. Recent Developments
  • 9.9. Biogen Idec
    • 9.9.1. Company Overview
    • 9.9.2. Financials
    • 9.9.3. Products & Services
    • 9.9.4. Recent Developments

List of Tables

  • Table 1: Global Recombinant Coagulation Factor Market Size, By Product,Through 2020 ($Million)
  • Table 2: Global Recombinant Coagulation Factor Market Size, By Geography, Through 2020 ($Million)
  • Table 3: Global Recombinant Factor VIII Market Size, By Country/Region, Through 2020 ($Million)
  • Table 4: Global Recombinant Factor IX Market Size, By Country/Region, Through 2020 ($Million)
  • Table 5: Global Von Willebrand factor Market Size, By Country/Region, Through 2020 ($Million)
  • Table 6: Global Recombinant Coagulation Factor Market Size, By Hemophilia Type, Through 2020 ($Million)
  • Table 7: Global Recombinant Coagulation Factor Market Size, By Geography, Through 2020 ($Million)
  • Table 8: Global Recombinant Coagulation Factor Market Size, For Hemophilia A, Through 2020 ($Million)
  • Table 9: Global Recombinant Coagulation Factor Market Size, For Hemophilia B, Through 2020 ($Million)
  • Table 10: Global Recombinant Coagulation Factor Market Size, By end-user, Through 2020 ($Million)
  • Table 11: Global Recombinant Coagulation Factor For Hospitals And Clinics, By Country/Region, Through 2020 ($Million) )
  • Table 12: Global Recombinant Coagulation Factor For Research Organizations, By Country/Region, Through 2020 ($Million)
  • Table 13: Global Recombinant Coagulation Factor For Academic Institutes, By Country/Region, Through 2020 ($Million)
  • Table 14: North America: Recombinant Coagulation Factor Market Size, By Country, Through 2020 ($Million)
  • Table 15: North America: Recombinant Coagulation Factor Market Size, By Products, Through 2020 ($Million)
  • Table 16: North America: Recombinant Coagulation Factor Market Size, By Hemophilia Type, Through 2020 ($Million)
  • Table 17: North America: Recombinant Coagulation Factor Market, By End User, Through 2020 ($Million)
  • Table 18: U.S.: Plasma Fractionation Market Size, By Products, Through 2020 ($Million)
  • Table 19: U.S.: Recombinant Coagulation Factor Market Size, By Product, Through 2020 ($Million)
  • Table 20: U.S.: Recombinant Coagulation Factor Market Size, By Hemophilia Type, Through 2020 ($Million)
  • Table 21: U.S.: Recombinant Coagulation Factor Market Size, By End User, Through 2020 ($Million)
  • Table 22: Canada: Recombinant Coagulation Factor Market Size, By Products, Through 2020 ($Million)
  • Table 23: Canada: Recombinant Coagulation Factor Market Size, By Hemophilia Type, Through 2020 ($Million)
  • Table 24: Canada: Recombinant Coagulation Factor Market Size, By End Users, Through 2020 ($Million)
  • Table 25: Europe: Recombinant Coagulation Factor Market Size, By Country/Region, Through 2020 ($Million)
  • Table 26: Europe: Recombinant Coagulation Factor Market Size, By Products, Through 2020 ($Million)
  • Table 27: Europe: Recombinant Coagulation Factor Market Size, By Hemophilia Type, Through 2020 ($Million)
  • Table 28: Europe: Recombinant Coagulation Factor Market Size, By End Users, Through 2020 ($Million)
  • Table 29: Germany: Recombinant Coagulation Factor Market Size, By Products, Through 2020 ($Million)
  • Table 30: Germany: Recombinant Coagulation Factor Market Size, By Hemophilia Type, Through 2020 ($Million)
  • Table 31: Germany: Recombinant Coagulation Factor Market Size, By End Users, Through 2020 ($Million)
  • Table 32: U.K.: Recombinant Coagulation Factor Market Size, By Products, Through 2020 ($Million)
  • Table 33: U.K.: Recombinant Coagulation Factor Market Size, By Hemophilia Type , Through 2020 ($Million)
  • Table 34: U.K.: Recombinant Coagulation Factor Market Size, By End Users, Through 2020 ($Million)
  • Table 35: France: Recombinant Coagulation Factor Market Size, By Products, Through 2020 ($Million)
  • Table 36: France: Recombinant Coagulation Factor Market Size, By Hemophilia Type , Through 2020 ($Million)
  • Table 37: France: Recombinant Coagulation Factor Market Size, By End Users, Through 2020 ($Million)
  • Table 38: Italy: Recombinant Coagulation Factor Market Size, By Products, Through 2020 ($Million)
  • Table 39: Italy: Recombinant Coagulation Factor Market Size, By Hemophilia Type , Through 2020 ($Million)
  • Table 40: Italy: Recombinant Coagulation Factor Market Size, By End Users, Through 2020 ($Million)
  • Table 41: Spain: Recombinant Coagulation Factor Market Size, By Products, Through 2020 ($Million)
  • Table 42: Spain: Recombinant Coagulation Factor Market Size, By Hemophilia Type , Through 2020 ($Million)
  • Table 43: Spain: Recombinant Coagulation Factor Market Size, By End Users, 2015-2020 ($Million)
  • Table 44: ROE: Recombinant Coagulation Factor Market Size, By Products, 2015-2020 ($Million)
  • Table 45: ROE: Recombinant Coagulation Factor Market Size, By Hemophilia Type , 2015-2020 ($Million)
  • Table 46: ROE: Recombinant Coagulation Factor Market Size, By End Users, Through 2020 ($Million)
  • Table 47: Asia-Pacific: Recombinant Coagulation Factor Market Size, By Country/Region, Through 2020 ($Million)
  • Table 48: Asia-Pacific: Recombinant Coagulation Factor Market Size, By Products, Through 2020 ($Million)
  • Table 49: Asia-Pacific: Recombinant Coagulation Factor Market Size, By Hemophilia Type , Through 2020 ($Million)
  • Table 50: Asia-Pacific: Recombinant Coagulation Factor Market Size, By End Users, Through 2020 ($Million)
  • Table 51: Japan: Recombinant Coagulation Factor Market Size, By Products, Through 2020 ($Million)
  • Table 52: Japan: Recombinant Coagulation Factor Market Size, By Hemophilia Type , Through 2020 ($Million)
  • Table 53: Japan: Recombinant Coagulation Factor Market Size, By End Users, Through 2020 ($Million)
  • Table 54: China: Recombinant Coagulation Factor Market Size, By Products, Through 2020 ($Million)
  • Table 55: China: Recombinant Coagulation Factor Market Size, By Hemophilia Type , Through 2020 ($Million)
  • Table 56: China: Recombinant Coagulation Factor Market Size, By End Users, Through 2020 ($Million)
  • Table 57: India: Recombinant Coagulation Factor Market Size, By Products, Through 2020 ($Million)
  • Table 58: India: Recombinant Coagulation Factor Market Size, By Hemophilia Type , Through 2020 ($Million)
  • Table 59: India: Recombinant Coagulation Factor Market Size, By End Users, Through 2020 ($Million)
  • Table 60: Rest Of Asia-Pacific: Recombinant Coagulation Factor Market Size, By Products, Through 2020 ($Million)
  • Table 61: Rest Of Asia-Pacific: Recombinant Coagulation Factor Market Size, By Hemophilia Type, Through 2020 ($Million)
  • Table 62: Rest Of Asia-Pacific: Recombinant Coagulation Factor Market Size, By End User,Through 2020 ($Million)
  • Table 63: ROW: Recombinant Coagulation Factor Market Size, By Country/Region, 2015-2020 ($Million)
  • Table 64: ROW: Recombinant Coagulation Factor Market Size, By Products, Through 2020 ($Million)
  • Table 65: ROW: Recombinant Coagulation Factor Market Size, By Hemophilia Type, Through 2020 ($Million)
  • Table 66: ROW: Recombinant Coagulation Factor Market Size, By End User, Through 2020 ($Million)
  • Table 67: Latin America: Recombinant Coagulation Factor Market Size, By Products, Through 2020 ($Million)
  • Table 68: Latin America: Recombinant Coagulation Factor Market Size, By Hemophilia Type , Through 2020 ($Million)
  • Table 69: Latin America: Recombinant Coagulation Factor Market Size, By End User, Through 2020 ($Million)
  • Table 70: Middle East & Africa: Recombinant Coagulation Factor Market Size, By Products, Through 2020 ($Million)
  • Table 71: Middle East & Africa: Recombinant Coagulation Factor Market Size, By Hemophilia Type,Through 2020 ($Million)
  • Table 72: Middle East & Africa: Recombinant Coagulation Factor Market Size, By End User, Through 2020 ($Million)
  • Table 72: New Product Launches, 2012-2015
  • Table 73: Expansions, 2012-2015
  • Table 74: Mergers And Acquisitions, 2012-2015
  • Table 75: Agreements, Partnerships, Collaborations, And Joint Ventures, 2012-2015

List of Figures

  • Figure 1: Recombinant Coagulation Factor VIII will dominate the market
  • Figure 2: Hemophilia A will dominate the Global Recombinant Coagulation Market
  • Figure 3: Hospital and Clinics will dominate the Global Recombinant Coagulation Market
  • Figure 4: Baxter International Inc.: Financial Detail
  • Figure 5: Octapharma AG: Financial Detail
  • Figure 6: Bayer AG: Financial Detail
  • Figure 7: CSL Ltd.: Financial Detail
  • Figure 8: Grifols International SA: Financial Detail
  • Figure 9: Kedrion S.P.A.: Financial Detail
  • Figure 10: Novo Nordisk A/S: Financial Detail
  • Figure 12: Biogen Idec: Financial Detail
  • Figure 13: Pfizer Inc. : Financial Detail
Back to Top